Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Autolus Therapeutics ( (AUTL) ) has issued an announcement.
On January 12, 2026, Autolus reported preliminary unaudited net product revenue from AUCATZYL of about $24 million for the fourth quarter of 2025 and approximately $75 million for full-year 2025, the first year of commercial sales, supported by a US launch across more than 60 treatment centers and initial approvals in the UK and EU. The company issued 2026 AUCATZYL revenue guidance of $120 million to $135 million, highlighted real-world data from the ROCCA consortium confirming strong efficacy and a favorable safety profile, and outlined a strategy to drive top-line growth, turn gross margin positive through manufacturing efficiencies, and extend obe-cel into pediatric B-ALL, lupus nephritis, progressive multiple sclerosis and AL amyloidosis, while indicating its current cash resources should fund operations into the fourth quarter of 2027, though all 2025 figures remain preliminary and subject to audit adjustments.
The most recent analyst rating on (AUTL) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Autolus Therapeutics stock, see the AUTL Stock Forecast page.
Spark’s Take on AUTL Stock
According to Spark, TipRanks’ AI Analyst, AUTL is a Neutral.
The score is held back primarily by weak profitability and negative cash flow despite improving revenue, while technicals are supportive with strong momentum but overbought signals. Earnings-call execution on the Obe-cel launch is a positive driver, but high cost of sales and continued losses temper the outlook; valuation is constrained by negative earnings.
To see Spark’s full report on AUTL stock, click here.
More about Autolus Therapeutics
Autolus Therapeutics plc is a commercial-stage biopharmaceutical company focused on developing, manufacturing and delivering next-generation programmed T cell therapies for cancer and autoimmune diseases. Its lead marketed product, AUCATZYL (obecabtagene autoleucel; obe-cel), is a CD19-directed CAR T cell therapy for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia, and the company is advancing a pipeline of T cell therapies targeting hematological malignancies, solid tumors and autoimmune indications.
Average Trading Volume: 2,904,655
Technical Sentiment Signal: Sell
Current Market Cap: $508.3M
For a thorough assessment of AUTL stock, go to TipRanks’ Stock Analysis page.